Clinical trial · Interventional
HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies
NCT03232268CI-TRIAL-00105375MICROSTEMcompletedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims at evaluating the safety of an approach based on HLA-mismatched Microtransplantation without immunosuppressive treatment in patients With myeloid hemopathies who are ineligible to conventional allograft
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HLA-mismatched microtransplantation | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- HLA-mismatched microtransplantation
- description
- HLA-mismatched microtransplantation without immunosuppressive treatment
- interventionNames
- Biological: HLA-mismatched microtransplantation
Primary outcomes (1)
- measure
- Occurrence of acute Graft versus Host disease after a HLA-mismatched transplantation without an immunosuppressive treatment
- timeFrame
- 100 days after transplantation
- description
- Cumulative incidence of acute GVH (grade 1 to 4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\> or = 65 years with a myeloid hemopathy in Complete Remission or Complete remission with incomplete hematological recovery or Age\<65 years with an ineligibility to allograft (contraindication to conditioning) * HLA-partially matched family donors * Affiliated to(or beneficiary of) the Social Security * Informed consent signed Exclusion Criteria: * AML3 * Previous Hematopoietic Stem Cell TRansplantation * Uncontrolled infection -PS\>3 -Other progressive cancer * Psychiatric disease * Vulnerable person or unable to provide informed consent * Emergency * Unable to comply with required study follow up
References
Publications (0)
Data not yet available
No reference posted for this study.